Blueprint Medicines should be bought on any weakness, says Stifel

Keeping a Buy rating and $155 price target on Blueprint Medicines (BPMC), Stifel says the market is disappointed that 2025 Ayvakit guidance brackets consensus, given those same consensus sources don’t exceed management’s $2B 2030 target. The straight-line absolute sales dollar math also necessitates an acceleration during years 4-8 of the ISM launch where it is reasonable to assume a new market launch should instead be maturing. While last year Blueprint’s management also set a low/beatable full year guide, these factors create the investor question pressuring shares, the firm notes. Stifel recommends investors buy on weakness.